1. Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation
- Author
-
Gioele Fabbri, Matteo Serenelli, Marco Manfrini, Veria Vacchiano, Rosaria Plasmati, Fabrizio Salvi, Alessandra Ferlini, Claudio Rapezzi, and Francesca Pastorelli
- Subjects
Pathology ,medicine.medical_specialty ,Amyloidosis ,cardiomyopathy ,Ile88Leu ,polyneuropathy ,transthyretin ,Cardiomyopathy ,030204 cardiovascular system & hematology ,NO ,03 medical and health sciences ,0302 clinical medicine ,Internal Medicine ,medicine ,Humans ,Prealbumin ,Amyloid Neuropathies, Familial ,biology ,business.industry ,nutritional and metabolic diseases ,medicine.disease ,Transthyretin ,Phenotype ,Mutation ,Mutation (genetic algorithm) ,biology.protein ,Cardiomyopathies ,business ,Polyneuropathy ,030217 neurology & neurosurgery ,Attr amyloidosis - Abstract
Ile68Leu transthyretin-related amyloidosis (ATTR) is known as a mainly or exclusively cardiogenic variant. We hypothesized that an accurate specialized neurological evaluation could reveal a consistent frequency of mixed phenotypes.Forty-six consecutive subjects with transthyretin (TTR) Ile68Leu (p.Ile88Leu) mutation (29 patients and 17 unaffected carriers) underwent an in-depth cardiac and neurologic evaluation at a single center.All 29 patients showed cardiac involvement. In 20 (69%) cases, it was associated with neurological abnormalities (i.e. a mixed phenotype): 10 (35% of the total) had signs and symptoms of neuropathy, 5 (17%) had abnormalities at the neurologic specialist examination but without symptoms, and 5 (17%) had abnormal nerve conduction study only. None of the asymptomatic carriers showed neurological abnormalities or cardiac involvement. The Neuropathy Impairment Score was5 in seven patients at baseline, and became5 in six more patients during follow-up. The probability of experiencing a major adverse cardiac event (MACE) during follow-up was higher in the mixed than cardiologic phenotype (At least two-thirds of patients with Ile68Leu ATTR and amyloidotic cardiomyopathy show an associated - definite or probable - neurologic impairment of variable degree if accurately evaluated in a neurologic setting. This proportion can rise during follow-up. The mixed phenotype carries a worse prognosis compared to the exclusively cardiologic one. These observations show that more patients could be eligible for treatment with gene silencers than currently indicated and highlight the need for an in-depth and continuous multidisciplinary evaluation of Ile68Leu ATTR patients.
- Published
- 2021
- Full Text
- View/download PDF